In a small exploratory double-blind, placebo-controlled, cross-over study, ten adults with migraine received a single oral dose of psilocybin (0.143 mg/kg) or placebo, with sessions two weeks apart. Over the two weeks following administration, psilocybin reduced weekly migraine days by an average of 1.65 days (95% CI: -2.53 to -0.77), significantly more than placebo, which reduced them by 0.15 days (95% CI: -1.13 to 0.83). The reduction in migraine frequency was not linked to the intensity of acute psychedelic effects. Psilocybin was well-tolerated with no serious adverse events. The findings suggest a lasting therapeutic benefit from a single dose, independent of acute psychological effects.
A subset of patients in a minimally conscious state show improved behavioral responsiveness after transcranial direct current stimulation (tDCS) of the left dorsolateral prefrontal cortex, while those who are unresponsive show limited benefit. Among 131 patients, 32% of minimally conscious patients responded to tDCS, compared to 10% of unresponsive patients. A regression model using baseline diagnosis, Coma Recovery Scale-Revised Index, age, sex, and time since injury correctly identified responders 77% of the time. Patients in a minimally conscious state with better cognitive profiles and longer time since injury appear to respond better to tDCS, suggesting they are better candidates for this treatment.